Skip to Content

Management of Nausea and Vomiting Following First-Line Zolbetuximab + Chemotherapy

Nausea and vomiting emerged as the most frequent treatment-related adverse events among patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma treated with zolbetuximab plus chemotherapy. In this MEDtalk, Dr. Kohei Shitara elaborates the management strategies for these side effects.

Kohei Shitara

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top